Rafael (NYSE:RFL) Trading Up 4.6% – Here’s What Happened

Rafael Holdings, Inc. (NYSE:RFL)’s stock price shot up 4.6% on Tuesday . The company traded as high as $3.49 and last traded at $3.3050. 472,465 shares were traded during mid-day trading, an increase of 50% from the average session volume of 316,004 shares. The stock had previously closed at $3.16.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised Rafael from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Rafael has an average rating of “Sell”.

Rafael Trading Down 16.6%

The company has a market cap of $164.01 million, a price-to-earnings ratio of -4.64 and a beta of 0.28. The stock’s 50 day moving average price is $1.78 and its 200 day moving average price is $1.45.

Rafael (NYSE:RFL) last announced its quarterly earnings data on Thursday, June 11th. The company reported ($0.08) earnings per share (EPS) for the quarter. Rafael had a negative net margin of 3,321.74% and a negative return on equity of 41.27%. The company had revenue of $0.18 million for the quarter.

Hedge Funds Weigh In On Rafael

Institutional investors have recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in Rafael in the second quarter valued at $50,000. Renaissance Technologies LLC boosted its stake in Rafael by 59.1% during the 1st quarter. Renaissance Technologies LLC now owns 89,138 shares of the company’s stock valued at $111,000 after purchasing an additional 33,111 shares in the last quarter. Citadel Advisors LLC boosted its position in shares of Rafael by 132.3% during the 3rd quarter. Citadel Advisors LLC now owns 72,584 shares of the company’s stock valued at $99,000 after purchasing an additional 41,335 shares in the last quarter. Geode Capital Management LLC increased its stake in Rafael by 25.4% in the 4th quarter. Geode Capital Management LLC now owns 445,866 shares of the company’s stock worth $526,000 after purchasing an additional 90,417 shares in the last quarter. Finally, Cable Car Capital LP acquired a new position in Rafael during the second quarter valued at $173,000. Institutional investors and hedge funds own 11.30% of the company’s stock.

Rafael Company Profile

Rafael Holdings, Inc primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. It operates in two segments, Healthcare and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is CPI-613 (devimistat), currently under Phase III clinical study for the treatment of metastatic pancreatic cancer and acute myeloid leukemia.